| ¿µ¹® | visual field test | ÇÑ±Û | ½Ã¾ß°Ë»ç |
|---|---|---|---|
| ¼³¸í | ´«À» ÇѰ÷¿¡ °íÁ¤½ÃŲ ä, °üÂûÇÒ ¼ö ÀÖ´Â ÁÖº¯°ø°£À» ½Ã¾ß¶ó ÇÑ´Ù. ½Ã¾ß¸¦ °Ë»çÇÏ´Â °¡Àå °£´ÜÇÑ ¹æ¹ýÀº ´ë¸é°Ë»ç(confronting test)ÀÌ´Ù. À̰ÍÀº Çǰ˻çÀÚÀÇ ´«À» °Ë»çÀÚÀÇ ´«¿¡ ¸ÂÃß¾î º¸µµ·Ï ÇÏ¿© ´«À» °íÁ¤½ÃŲä, °Ë»çÀÚ°¡ ¼Õ°¡¶ô³¡À» À§ÂÊ, ¾Æ·¡ÂÊ, ¿ÞÂÊ, ¿À¸¥ÂÊ, ±×¸®°í ºñ½ºµëÈ÷ °æ»çÁø °÷ µîÀ¸·Î ¿Å°Üº¸¾Æ Çǰ˻çÀÚ°¡ °üÂûÇÒ ¼ö ÀÖ´ÂÁö ¿©ºÎ¸¦ Á¤ÇÏ´Â °Ë»ç¹ýÀÌ´Ù. À̺¸´Ù Á¤È®ÇÑ °Ë»ç¹ýÀº ÀÚµ¿½Ä ÄÄÇ»Åͽþ߰˻ç¹ýÀÌ ÀÖ´Ù. ´ë°³, ´«ÀÚüÀÇ ÀÌ»óÀÌ À־ ½Ã¾ß°Ë»ç¿¡¼ ÀÌ»óÀÌ ³ª¿ÀÁö¸¸, ÀÌ¿Ü ³úÀÇ ÀÌ»óÀ¸·Î ½Ã°¢ÀÇ Çü¼º°æ·Î¿¡ ÀÌ»óÀÌ À־ ¿ª½Ã ÀÌ»ó¼Ò°ßÀ» º¸ÀδÙ. |
||
| ¿µ¹® | Draw a person test | ÇÑ±Û | Àι°È ¼º°Ý°Ë»ç |
|---|---|---|---|
| ¼³¸í | Àι°È ¼º°Ý°Ë»ç´Â óÀ½¿¡´Â Áö´É°Ë»ç·Î °³¹ßµÇ¾ú°í, ±× ÈÄ¿¡´Â »ç¶÷ÀÇ ¹«ÀǽÄÀÇ ¿ä¼Ò¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î ¹ßÀüÇÏ¿´´Ù. °Ë»çÀç·á´Â Áö¿ì°³°¡ ÀÖ´Â ¿¬Çʰú ¹éÁö¸¦ ÇǰËÀÚ¿¡°Ô ÁÖ°í, »ç¶÷À» ±×·Áº¸¶ó´Â Áö½Ã¸¦ Çϸç, °Ë»çÀÚ´Â ±×¸®´Â ¼ø¼¿Í Æò°¡¸¦ ±â·ÏÇϰí, ´Ù ±×¸° ÈÄ¿¡´Â ¸ÕÀú¿Í ´Ù¸¥ À̼ºÀ» ±×¸®µµ·Ï ÇÑ´Ù. ÀÌ °Ë»ç¿¡¼ÀÇ ½ÅüÀÇ ¸ð¾çÀº °ð ÀھƻóÀ» ¹Ý¿µÇÑ´Ù´Â ÀÔÀå, ±×¸²¿¡¼ °Á¶µÈ ±â°üÀº ÀÇ»ç¼ÒÅë¼ö´Ü, °ü³äÈ, ¿å±¸Ã¼°è, ¼ºÀû ´É·Â, °¥µî, ÁÂÀý°æÇè, ¼ºÀå·Â µîÀ» ¹Ý¿µÇÑ´Ù°í ÇÑ´Ù. À̰ÍÀº ¾Æµ¿°ú ¼ºÀο¡°Ô °³º°Àû ¶Ç´Â Áý´ÜÀûÀ¸·Î ½Ç½ÃÇÒ ¼ö ÀÖ°í, °£ÆíÇϸ鼵µ À¯ÀÍÇÑ °ÍÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ³úÀÇ ±âÁúÀû º¯È¸¦ ¾Ë¾Æ³»±â À§ÇÑ ¸ñÀûÀ¸·Îµµ ¸¹ÀÌ ÀÌ¿ëµÈ´Ù. |
||
| ¿µ¹® | intelligence test | ÇÑ±Û | Áö´É°Ë»ç |
|---|---|---|---|
| ¼³¸í | 1905³â ÇÁ¶û½ºÀÇ ºñ³×°¡ Á¤½Å¹Ú¾à¾Æ¸¦ ÀϹݾƵ¿À¸·ÎºÎÅÍ ÆÇº°Çϱâ À§ÇÏ¿© ÀÛ¼ºÇÑ °ÍÀÌ Áö´É°Ë»çÀÇ ½ÃÀÛÀÌ´Ù. Áö´É°Ë»ç´Â ±×ÀÇ ¸ñÀûÀ¸·ÎºÎÅÍ ÀϹÝÀû Áö´É°Ë»ç¿Í Áø´Ü¿ë Áö´É°Ë»ç·Î ³ª´²Áö°í, ½Ç½Ã¹æ¹ý¿¡¼ °³Àοë(°³º°½Ä)°ú Áý´Ü¿ë(´Üü½Ä)À¸·Î ºÐ·ùµÇ°í ¶Ç ¹®Á¦ÀÇ ³»¿ëÀ¸·ÎºÎÅÍ ¾ð¾î¼º°Ë»ç(A½Ä ¶Ç´Â ¥á½Ä)¿Í ºñ¾ð¾î¼º°Ë»ç(B½Ä ¥â½Ä)·Î ³ª´²Áø´Ù. Áö´É°Ë»çÀÇ °á°úÀÇ Ç¥½Ã¹ýÀº Á¤½Å¿¬·É(mental age, MA), Áö´ÉÁö¼ö(intelligence quotient, IQ), Áö´ÉÆíÂ÷Ä¡(intelligence standard score, ISS)µîÀÌ ÀÖ´Ù. Áö´É°Ë»ç¿¡´Â ¿ª»çÀûÀ¸·Î ºñ³×½Ä°ú À°±º½ÄÀÇ µÎ °èÅëÀÌ ÀÖ´Ù. ºñ³×½ÄÀº °Ë»çÀÚ°¡ °³º°ÀûÀ¸·Î ÇÑ °³ ¹®Ç×¾¿ Áú¹®À» Çϸé ÀÌ¿¡ ´ëÇÏ¿© Çǰ˻çÀÚ°¡ ¸»À̳ª ÇൿÀ¸·Î ÀÀ´äÇÏ´Â ¹æ¹ý(°³º°½Ä-¹®´ä½Ä)À̰í, À°±º½ÄÀº ÀϹÝÀûÀÎ ¹æ½ÄÀ¸·Î´Â ÀμâµÈ ¹®Á¦¿ëÁö¸¦ »ç¿ëÇÏ¿© Çǰ˻çÀÚ°¡ ¼ÒÁ¤ÀÇ ½Ã°£ ³»¿¡ µÇµµ·Ï ¸¹ÀÌ ¹Ù¸£°Ô(½Ã°£Á¦Çѹý) ȸ´äÀ» ±âÀÔÇÑ´Ù(Çʱâ¹ý). Çѱ¹ ÃÖÃÊÀÇ Áö´É°Ë»ç´Â 1954³â ¼¿ï´ëÇб³ »ç¹ü´ëÇÐ ±³À°½É¸®¿¬±¸½Ç¿¡¼ Á¦ÀÛÇÑ °£Æí Áö´É°Ë»çÀÌ´Ù. °£Æí Áö´É°Ë»ç ÀÌÈÄ ´Ù¼öÀÇ Áý´Ü Áö´É°Ë»ç°¡ ÃâÇöÇÏ¿´´Âµ¥ ºñ±³Àû ÃÖ±Ù¿¡ Ç¥ÁØÈµÈ Áö´É°Ë»ç·Î´Â Çѱ¹Çൿ°úÇבּ¸¼Ò°¡ 1984³â¿¡ Àü±¹ °íµîÇб³ ÇлýÀ» ´ë»óÀ¸·Î Á¦ÀÛÇÑ KIT-S Áö´É°Ë»ç°¡ ÀÖ´Ù. |
||
| ¿µ¹® | patch test | ÇÑ±Û | øÆ÷°Ë»ç |
|---|---|---|---|
| ¼³¸í | ÇǺξ˷¹¸£±â¿¡ ´ëÇÑ °Ë»ç¹æ¹ýÀ¸·Î Ç׿øÀ» ºÙÀΠøÆ÷¸¦ ÇǺο¡ ºÎÂøÇÑ ´ÙÀ½ 2ÀÏ ÈÄ¿¡ »çÇϰí, ´Ù½Ã 2ÀÏ ÈÄ¿¡ °Ë»çÇÑ´Ù. 2¹ø ¸ðµÎ ÇǺÎÀÌ»óÀÌ ³ªÅ¸³ª¸é, ¾Ë·¹¸£±â¹ÝÀÀ¿¡ ÀÇÇÑ ÀÌ»ó¼Ò°ßÀ̸ç, ¸¸¾à óÀ½ 2ÀÏ¿¡´Â ÀÌ»óÀÌ ÀÖÁö¸¸, ´ÙÀ½ 2ÀÏ ÈÄ °Ë»ç¿¡¼ ÀÌ»ó¼Ò°ßÀÌ ¾øÀ¸¸é, ±×°ÍÀº ´ÜÁö ÇǺÎÀڱؿ¡ ÀÇÇÑ ÀÌ»ó¼Ò°ßÀÏ »ÓÀÌ´Ù. |
||
| ¿µ¹® | hearing test | ÇÑ±Û | û·Â°Ë»ç |
|---|---|---|---|
| ¼³¸í | ±Í°¡ µé¸®´Â Á¤µµ¸¦ ÃøÁ¤ÇÏ´Â °Ë»ç. û°¢°Ë»ç¶ó°íµµ ÇÑ´Ù. ¼Ò¸®³ª ¸ñ¼Ò¸®°¡ Àß µé¸®´ÂÁöÀÇ ¿©ºÎ µî û°¢ÀÇ ¿¹¹ÎÇÑ Á¤µµ¸¦ ÃøÁ¤ÇÏ´Â ÀÏÀÌ´Ù. °Ë»ç¿¡´Â û·Â°è³ª ¼Ò¸®±Á¼è µîÀÇ ±â±¸¿¡ ÀÇÇØ¼ ¾ò´Â À½¿ø, Áï ¼øÀ½À» »ç¿ëÇϸç, »ç¶÷ÀÇ ¸ñ¼Ò¸®³ª ½Ã°è¼Ò¸® µîµµ À½¿øÀ¸·Î »ç¿ëµÈ´Ù. ¶Ç À½ÆÄ°¡ ÀüÆÄµÇ´Â ¸ÅÁú¿¡ µû¶ó ±âµµ û·Â°Ë»ç¿Í °ñµµ û·Â°Ë»ç·Î ±¸º°µÇ±âµµ ÇÑ´Ù. °Ë»çÀÇ ³»¿ëÀ¸·Î´Â û°¢ÀÇ »óÇÏÀ½°è³ª ÃÖ¼Ò °¡Ã»¹®ÅΰªÀÇ °Ë»ç¸¦ ºñ·ÔÇÏ¿©, ÃæºÐÈ÷ µé¸®´Â ¼Ò¸®¸¦ »ç¿ëÇÏ¿© ±×°ÍÀÌ µé¸®´Â »óŸ¦ Á¶»çÇÏ´Â ¹®Åΰª°Ë»ç(¼Ò¸®ÀÇ Å©±â¿Í »óÅÂÀÇ °Ë»ç, ¼¼±âÀÇ ÆÇº°¿ª°Ë»ç µî) ¿Ü¿¡ À½ÇâÀÚ±ØÀÇ ¹ÝÀÀÀ¸·ÎºÎÅÍ Å¸°¢ÀûÀ¸·Î Á¶»çÇÏ´Â ¹æ¹ýµµ ÀÖÀ¸¸ç, À̰ÍÀº ÁÖ·Î °«³¾Æ±â³ª Á¤½Åº´È¯ÀÚ¿¡ ´ëÇÏ¿© »ç¿ëµÈ´Ù. ÁַΠû·Â°è°¡ »ç¿ëµÇ°í, û·ÂÀº µ¥½Ãº§(dB)·Î Ç¥½ÃµÈ´Ù. Á¤»óÀÎÀº 0dBÀ̰í, ³Ã»ÀÚÀϼö·Ï ±× ¼ö°¡ Ä¿Áö¸ç, 60dBÀÌ»óÀº »ó´çÈ÷ ³Ã»À̰í, 80dB ÀÌ»óÀÌ¸é ±Í¸Ó°Å¸®ÀÌ´Ù. |
||
| IT | immunological test; immunotherapy; implantation test; individual therapy; information technology; in... |
|---|---|
| LFT | latex fixation test; latex flocculation test; left fronto-transverse [fetal position]; liver functio... |
| LTT | lactose tolerance test; leucine tolerance test; limited treadmill test; lymphocyte transformation te... |
| SAT | saliva alcohol test; satellite; serum antitrypsin; single-agent chemotherapy; slide agglutination te... |
| SRT | sedimentation rate test; simple reaction time; sinus node recovery time; sitting root test; speech r... |
| multiple amputation | Amputation of two or more limbs or parts of limbs performed at the same operation. (05 Mar 2000) |
|---|---|
| multiple anchorage | Anchorage in which more than one type of resistance unit is utilised. Synonym: reinforced anchorage. (05 Mar 2000) |
| multiple birth offspring | The offspring in multiple pregnancies (pregnancy, multiple): twins, triplets, quadruplets, quintuplets, etc. (12 Dec 1998) |
| multiple carboxylase deficiency | Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase. (12 Dec 1998) |
| multiple chemical sensitivity | An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61) (12 Dec 1998) |
| multiple cloning site | Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments. (18 Nov 1997) |
| multiple drug resistant tuberculosis | A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance. (09 Oct 1997) |
| multiple ego states | Various psychological organizational state's reflecting different personas or life experiences. (05 Mar 2000) |
| multiple embolism | Embolism caused by the arrest of a number of small emboli. (05 Mar 2000) |
| multiple endocrine adenomatosis | The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance. Synonym: multiple endocrine adenomatosis. (05 Mar 2000) |
| multiple endocrine deficiency syndrome | <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis. Synonym: multiple glandular deficiency syndrome. (05 Mar 2000) |
| multiple endocrine neoplasia | (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour. (type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. Origin: Gr. Plassein = to form (27 Sep 1997) |
| multiple endocrine neoplasia 1 | <radiology> Multiple endrocrine neoplasia syndrome three P's. Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%). Synonym: Wermer syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 2 | <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia Synonym: Sipple syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 3 | <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B Synonym: Schimke, marfanoid syndrome (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|